Compare Robinhood Markets, Inc. (HOOD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Robinhood (HOOD) trades at $109.51, down 2.22% today, with strong technical support at $108. The stock shows robust fundamentals with 2025 revenue reaching $4.47B and net income of $1.88B, representing 42% margins. Recent news highlights expansion into 24/7 stock trading and new product launches, positioning the company for continued growth in the e-brokerage sector.

Wall Street maintains a bullish outlook with 77% buy ratings and a $137 consensus price target, representing 25% upside potential. Key risks include valuation concerns with a 48.5 P/E ratio and execution challenges in new product rollouts. The company's transformation into a broader financial services platform provides long-term growth opportunities despite near-term volatility.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.